Cardiovascular Disease

Does Fenofibrate Help or Hurt Renal Function?

November 27, 2020

Dr. Paul D. Thompson tackles the topic of whether use of fenofibrate helps or harms kidney function.

Cardiometabolic Health: Future of Care or Detracting from Endocrinology?

November 25, 2020

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

Too Much Sitting, Lying Down Could Increase Heart Failure Risk by 42% in Older Women

November 24, 2020

An analysis of data from the Women's Health Initiative details the detrimental impact of sedentary behavior on the risk of heart failure in older women.

AliveCor's Kardia AI V2 Algorithm Suite Receives FDA Clearance

November 24, 2020

AliveCor announced the US FDA has granted 510(k) clearance to Kardia AI V2 algorithm suite.

Analysis Indicates Semaglutide Reduces MACE Regardless of Triglyceride Levels

November 23, 2020

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

November 21, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Is it Time to Consider Bariatric Surgery for Primary Prevention?

November 20, 2020

Dr. Gregory Weiss reflects on data related to bariatric surgery and its subsequent impact on cardiovascular health.

Comparing Cost-Effectiveness of Antidiabetic Therapies with Cardiovascular Benefit

November 19, 2020

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

November 18, 2020

TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.